RLAY
Price
$18.73
Change
-$1.27 (-6.35%)
Updated
Jul 13 closing price
Capitalization
4.08B
24 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$14.96
Change
-$0.89 (-5.62%)
Updated
Jul 13 closing price
Capitalization
1.11B
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RLAY vs XNCR

RLAY vs XNCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RLAY vs. XNCR commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLAY is a Buy and XNCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (RLAY: $20.00 vs. XNCR: $14.96)
Brand notoriety: RLAY and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLAY: 45% vs. XNCR: 46%
Market capitalization -- RLAY: $4.08B vs. XNCR: $1.11B
RLAY [@Biotechnology] is valued at $4.08B. XNCR’s [@Biotechnology] market capitalization is $1.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLAY’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • RLAY’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both RLAY and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLAY’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • RLAY’s TA Score: 5 bullish, 3 bearish.
  • XNCR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RLAY is a better buy in the short-term than XNCR.

Price Growth

RLAY (@Biotechnology) experienced а +7.27% price change this week, while XNCR (@Biotechnology) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +7.30%, and the average quarterly price growth was +1806.57%.

Reported Earning Dates

RLAY is expected to report earnings on Aug 06, 2026.

XNCR is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RLAY($4.08B) has a higher market cap than XNCR($1.11B). RLAY YTD gains are higher at: 121.395 vs. XNCR (-2.286). XNCR has higher annual earnings (EBITDA): -131.66M vs. RLAY (-293.61M). RLAY has more cash in the bank: 642M vs. XNCR (445M). RLAY has less debt than XNCR: RLAY (31.6M) vs XNCR (175M). XNCR has higher revenues than RLAY: XNCR (97.4M) vs RLAY (10.7M).
RLAYXNCRRLAY / XNCR
Capitalization4.08B1.11B368%
EBITDA-293.61M-131.66M223%
Gain YTD121.395-2.286-5,310%
P/E RatioN/AN/A-
Revenue10.7M97.4M11%
Total Cash642M445M144%
Total Debt31.6M175M18%
FUNDAMENTALS RATINGS
RLAY vs XNCR: Fundamental Ratings
RLAY
XNCR
OUTLOOK RATING
1..100
5032
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3438
P/E GROWTH RATING
1..100
105
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RLAY's Valuation (77) in the null industry is in the same range as XNCR (88) in the Biotechnology industry. This means that RLAY’s stock grew similarly to XNCR’s over the last 12 months.

RLAY's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that RLAY’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (98) in the Biotechnology industry is in the same range as RLAY (99) in the null industry. This means that XNCR’s stock grew similarly to RLAY’s over the last 12 months.

RLAY's Price Growth Rating (34) in the null industry is in the same range as XNCR (38) in the Biotechnology industry. This means that RLAY’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is in the same range as RLAY (10) in the null industry. This means that XNCR’s stock grew similarly to RLAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RLAYXNCR
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 20 days ago
84%
Bullish Trend 18 days ago
74%
Declines
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 1 day ago
78%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 1 day ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
RLAY
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SETH49.600.60
+1.22%
ProShares Short Ether ETF
IND22.83N/A
N/A
Xtrackers Nifty 500 India ETF
QMAR37.07-0.18
-0.48%
FT Vest Nasdaq-100 Buffer ETF – Mar
IMAR30.35-0.19
-0.62%
Innovator Intl Dev Pwr Bffr ETF - Mar
FNDE40.13-0.40
-0.99%
Schwab Fundamental Emerging MarketsEqETF

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with KURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
-6.37%
KURA - RLAY
49%
Loosely correlated
-4.72%
XNCR - RLAY
46%
Loosely correlated
-5.62%
IMNM - RLAY
44%
Loosely correlated
-2.36%
CGEM - RLAY
44%
Loosely correlated
-1.43%
VCYT - RLAY
44%
Loosely correlated
+0.90%
More